电影票房

您好,歡迎訪問中山大學腫瘤防治中心官方網站!
職工郵箱 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 陳忠平

    職務:膠質瘤單病種首席專家
    職稱:教授、主任醫師、博士生導師、膠質瘤首席專家
    專長:腦(神經系統)腫瘤的顯微外科手術和綜合治療
    一、基本情況
    職稱:教授、主任醫師、博士生導師、膠質瘤首席專家 
    職務:膠質瘤單病種首席專家
    專家門診時間: 周二上午;周五上午
    專業特長:從事神經外科臨床工作三十年,在神經外科疾病的診斷和治療方面擁有豐富的經驗。擅長腦(神經系統)各類腫瘤(包括膠質瘤,腦膜瘤,聽神經瘤,垂體瘤等)的顯微外科手術和綜合治療,特別是膠質瘤的個體化綜合治療和研究。

    二、學習工作經歷:
       1978年—1982年:蘇州醫學院醫學系本科畢業
       1982年12月—1993年:蘇州醫學院附一院神經外科工作;期間在職讀神經外科碩士(1989年畢業)和博士(1993年畢業)
       1993年 9月—1999年9月: 加拿大麥吉爾大學,神經外科博士后/ Research associate
       1999年11月至今:中山大學附屬腫瘤醫院心神經外科工作

    陳忠平
    主任醫師,博士導師,膠質瘤首席專家
    1957年8月生,男,漢族,江蘇江陰人
    門診時間:周二上午、周五上午

    教育和工作經歷
      1982年:蘇州醫學院本科畢業
      1982-1993年:蘇州醫學院附屬第一醫院神經外科  神經外科碩士(1989),神經外科博士(1993)
      1993-1996年:加拿大McGill 大學神經外科博士后
      1996-1999年:加拿大McGill 大學神經外科/腫瘤科Research associate
      1999年11月-:中山大學腫瘤防治中心神經外科/神經腫瘤科主任

    專業擅長
      從事神經外科醫療、教學和科研工作三十余年,在神經外科疾病的診斷和治療方面擁有豐富的經驗。對腦(神經系統)腫瘤的顯微外科手術和綜合治療具有較深的造詣,特別是腦膠質瘤的個體化綜合治療,采用包括依據腫瘤分子特征的預見性化療、CIK細胞局部免疫治療等使數以千計的病人獲得良好的治療效果。除了高超的臨床醫術之外,陳忠平教授還在基礎研究方面頗有建樹。在神經腫瘤分子生物學-尤其是膠質瘤耐藥/放射抗拒分子機制方面做了較深入的研究,在惡性腦腫瘤免疫治療的基礎和臨床應用方面也進行了探索。首先提出并用轉基因試驗證明,核苷酸切除修復系統中的重要因子 - ERCC2的表達與人腦腫瘤對烷化劑的耐藥相關;實驗和臨床研究證明DNA修復基因六氧甲基鳥嘌呤DNA甲基轉移酶基因(MGMT)表達影響人腦膠質瘤對氯乙基亞硝脲化療的效果,抑制MGMT活性可為化療增敏。還在國際上首先報道了膠質瘤也存在血管生成擬態現象(Vasculogenic Mimicry)(J Histochem Cytochem 2005,May)。發表學術論文300多篇,其中70多篇為SCI收錄雜志。獲包括WHO中國青年(神經科學)優秀論著獎(1993),加拿大神經科學學會獎(Francis McNaughton Memorial Prize)(1998)和王忠誠中國神經外科醫師年度獎(2006年度學術獎)等在內的國內、外多項學術獎勵。入選中國名醫百強榜(2014年、2016年:腦膠質瘤手術醫生 Top10)。

    主要社會兼職
      1. 中國抗癌協會神經腫瘤專業委員會主任委員(2004-2012)
      2. 廣州抗癌協會神經腫瘤專業委員會主任委員 (2001-2013)
      3. 廣東省抗癌協會神經腫瘤專業委員會主任委員 (2009-2013)
      4. 廣東省神經外科學會副主任委員
      5. Neuro-oncology 編委
      6. Brain Tumor Pathology 編委
      7. Neuro-oncology Practice 編委
      8. "癌癥"雜志常務編委
      9. "中國微侵襲神經外科雜志"編委
      10.  "廣東醫學" 雜志編委
      11. "中華神經外科疾病研究雜志"編委
      12. "中華神經外科雜志"特邀審稿專家
      13. 國家自然科學基金評審專家庫專家
      14. 衛生部全國腫瘤規范化診療專家委員會(顱腦腫瘤專家)

    主要著作
      1. 腦腫瘤分子外科學. 黃強 主編,陳忠平、蘭青 副主編。 中國科技出版社 1998年
      2. 膠質瘤. 黃強 、陳忠平、蘭青 主編, 中國科技出版社 2000年
      3. 神經系統腫瘤. 陳忠平主編,北京大學醫學出版社, 2009年1月
      4. 中樞神經系統常見腫瘤診療綱要. 陳忠平(編寫組長),北京大學醫學出版社, 2010年5月(第一版),2012年9(第二版)
      5. 神經系統腫瘤化療手冊。陳忠平、楊群英 主編,北京大學醫學出版社, 2012年2月(第一版)。

    代表性論文
    英文:
    1.Chen ZP,Malapetsa A,Marcantonio D,Mohr G,Brien S,Panasci LC.Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Research ,1996,56: 2475-2478.
    2.Chen ZP,Mohr G,Panasci LC.Correlation between GST-μgene expression and chloroethylnitrosourea resistance in human brain tumor cell lines. Acta Academicae Medicinae Suzhou,1996,2:59-64.
    3.Chen ZP,Malapetsa A,Brien S,Mohr G,Panasci LC.Quantitation of ERCC-2 expression by reverse-transcription polymerase chain reaction comparison to Northern blot analysis. Anal Biochem,1997,244: 50-54.
    4.Chen ZP,Malapetsa A,McQuillan A,Marcantonia D,Bello V,Mohr G,Remack J,Brent TP,Panasci LC.Evidence for nucleotide excision repair as a modifying factor of MGMT mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Molecular Pharmacology,1997,52: 815-820.
    5.Chen ZP,Yarosh D,Garcia Y,Tampieri D,Mohr G,Langleben A,Panasci LC.Clinical response of O6-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients.Neurosurgical Focus,1998,4(6):artical 3.
    6.Chen ZP,McQuillan A,Mohr G,Panasci LC.Excision repair cross-complementing rodent repair dificiency gene2 expression and chloroethylnitrosourea  resistance in human glioma cell lines. Neurosurgery,1998,42(5)1112-1119.
    7.Chen ZP,Remack J,Brent TP,Mohr G,Panasci LC.Extraneuronal Monoamine Transporter Expression vis-à-vis SauCNU Cytotoxicity in Human Tumor Cell Lines.Clinical Cancer Research, 1999,5:4186-4190.
    8.Chen ZP,Wang G,Huang Q,Sun ZF,Zhou LY,Wang AD,Panasci LC.Enhanced antitumor activity of SarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neuro-Oncology,1999,44:7-14.
    9.Chen ZP,Pan J,Huang Q,Sun ZF,Zhou LY,Wang AD.Antitumor efficacy of SarCNU in a Human Glioma Xenograft Model expressing both MGMT and Extraneuronal Monoamine Transporter.J Neuro-Oncology,2001,51:19-24.
    10.Chen ZP,Carter CA,Alley MC,Mohr G,Panasci LC.Both Extraneuronal Monoamine Transporter and O6-methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of SarCNU in Human Tumor Xenografts.J Pharmacol Exp Ther,2001,296(3):712-715.
    11.Wang ZM,Chen ZP,Xu ZY,Christodoulopoulos G,Bello V,Mohr G,Aloyz R,Panasci LC.In vitro evidence for homologous recombinational repair in resistance to melphalan.J Natl Cancer Inst,2001,93(19):1473-1478.
    12.Pan LX,Chen ZP,Liu YS,Zhao JH.Magnetic Resonance Imaging and Biological Markers in Pituitary Adenomas with Invasion of the Cavernous Sinus Space.J Neuro-oncology,2005, 74(1):71-76.
    13.Yue WY,Chen ZP.Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem.2005, 53(8):997-1002.
    14.Chen HY,Shao CJ,Shi HL,Mu YG,Sai K,Chen ZP.Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human gliomas.J Neuro-oncology,2007,82:257-262.
    15.Shao CJ,Fu J,Shi HL,Mu YG,Chen ZP.Activities of DNA-PK and Ku86, but not Ku70, may predictsensitivity to cisplatin in human gliomas.J Neurooncol,2008,89(1):27-35.
    16.Yue WY,Yu SH, Zhao SG,Chen ZP. Molecular markers relating to malignant progression in grade II astrocytoma. J Neurosurgery,2009,110(4):709-14.
    17.Fu J, Liu ZG, Liu XM, Chen FR, Shi HL, Pang JC, Ng HK, Chen ZP,Glioblastoma stem cells resistant to temozolomide-induceautophagy.chinese medical journal,2009,122(11):1255-1259.
    18.Fu J,Shao CJ,Chen FR,NG HK,Chen ZP.Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in Glioma Cell Lines.Neuro-oncology,2010,12(4):328-340.
    19.Chen HY,Shao CJ,Chen FR,Kwan AL,Chen ZP.Role of ERCC1 Promoter Hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer,2010,126(8):1255-1259.
    20.Liu XM,Zhang QP,Mu YG,Zhang XH,Sai K,Pang JC,Ng HK,Chen ZP.Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol,2011,(105 ):173-179.
    21.Chen YS,Jing ZT,Luo C,Zhuang MH,Xia JZ,Chen ZP,Wang YJ.Vasculogenic mimicry–potential target for glioblastoma therapy:an in vitro and in vivo study.Med Oncol,2012,29:324–331.
    22.Yue WY,Sai K,Wu QL,Xia YF,Yu SH,Chen ZP.Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.Chin J Cancer,2012,31(3):159-165.
    23.Jiang XB,Ke C,Han ZA,Lin SH,Mou YG,Luo RZ,Wu SX,Chen ZP.Intraparenchymal papillary meningioma of brainstem: case report and literature review.Jiang et al.World Journal of Surgical Oncology, 2012, 10:10.
    24.Cui L,Fu J,Pang JC, Qiu ZK,Liu XM,Chen FR, Shi HL,Ng HK,Chen ZP.Overexpression of IL-7 enhances cisplatin resistance in glioma.Cancer Biology & Therapy ,2012,13 :7,496-503.
    25.Shao CJ, Wu MW, Chen FR, Li C, Xia YF, Chen ZP. Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro. Chin Med J, 2012;125(24):4338-4343.
    26.Mu YG, Huang LJ, Li SY, Ke C, Chen Y, Jin Y, Chen ZP. Working memory and the identification of facial expression in patients with left frontal glioma. Neuro Oncol (2012) 14(suppl 4): iv81-iv89.
    27.Sai K, Yang QY,Shen D,Chen ZP. Chemotherapy for gliomas in mainland China: An overview. Oncology Letters ,2013,5: 1448-1452.
    28.Wang J, Sai K, Chen FR, Chen ZP.miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 2013 Jul;72(1):147-158
    29.Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP.TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro-oncology, 2013,15(10):1353-1365
    30.Sai K, Mou YG,Zeng J, Lv YC, Xi SY, Guan S, Zhang XH,Wang J,Ke C,Guo JG, Chen YS,Chen ZP.Neurosurgical interventions for patients with nasopharyngeal carcinoma: a single institution experience. World Journal of Surgical Oncology 2013, 11:227
    31.Li G, Zhang ZG, Jin TB,Liang HJ,Tu YY,Gong L, Chen zp andGao GD.High frequency of the X-chromosome inactivationin young female patients with high-grade glioma. Diagnostic Pathology 2013, 8:101.
    32.Chen Y-S and Chen Z-P. Vasculogenic mimicry: a novel target for glioma therapy.  Chin J Cancer; 2014; Vol. 33 Issue 2 ;74-79.
    33.Qiu ZK, Shen D, Chen YS, Yang QY,Guo CC,Feng BH, Chen ZP.Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer; 2014; Vol. 33 Issue 2 :115-122.
    34.Sai K, Li WY, Chen YS, Wang J, Guan S, Yang QY, Guo CC, Mou YG, Li WP, Chen ZP. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma. Am J Chin Med2014;42(2):485-503
    35.Sai K, Zhong MG, Wang J, Chen YS, Mou YG, Ke C, Zhang XH, Yang QY, Lin FH, Guo CC, Chen ZH, Zeng J, Lv YC, Li X, Gao WC,Chen ZP. Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. J Neurol Sci. 2014 Aug 15;343(1-2):60-5. doi: 10.1016/j.jns.2014.05.022. Epub 2014 May 17.
    36.Guo CC, Yang QY, Sai K,Chen ZP. Clinical Practice of Chemotherapy with Temozolomide in China. Chemotherapy: open Access,2014, 3(2)
    37. Sai K, Chen ZP. What can Neurosurgeons Do for Brain Tumor Patients: 15-Year Experience at a Cancer Center. Austin J Neurosurg. 2014,1(4) :3
    38.Zhang J, Sai K, Wang J, Chen YS, Yan SM, Chen ZP. Ectopic cortical anaplastic ependymoma: An unusual case report and literature review. Clin Neurol Neurosurg. 2014 Jul 2;124C:142-145.
    39.Sun YC, Wang J, Guo CC, Sai K, Wang J, Chen FR, Yang QY, Chen YS, Wang J, To TS, Zhang ZP, Mu YG, Chen ZP*. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 2014 Aug 25;14:611.
    40.Qun-ying Yang, Cheng-cheng Guo, Zhong-ping. Chen. Profile of nimotuzumab in the treatment of high-grade glioma. OncoTargets and Therapy 2015:8 819–825.
    41.ZE-SHUN ZHANG, JING WANG, YOU-BI SHEN, CHENG-CHENG GUO, KE SAI, FU-RONG CHEN, XIN MEI, FU HAN and ZHONG-PING CHEN. Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy.ONCOLOGY LETTERS 10: 379-383, 2015
    42.Dong Shen, Cheng-cheng Guo , Jing Wang, Zhi-kun Qiu, Ke Sai , Qun-ying Yang, Yin-sheng Chen, Fu-rong Chen , Jie Wang, Lawrence Panasci, Zhong-ping Chen 。 Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells。 Oncology Reports 2015,34:2715-2721.
    43.Jing Wang, Yi-ying Zhao, Jian-feng Li, Cheng-cheng Guo, Fu-rong Chen, Hong-kai Su, Hua-fu Zhao, Ya-kang Long, Jian-yong Shao, Shing-shun Tony To, Zhong-ping Chen . IDH1 mutation detection by droplet digital PCR in glioma. Oncotarget. 2015 Nov 24;6(37):39651-39660.
    44.Yang QY, Guo CC, Deng ML, Wang J, Wang J, Lin FH, Zhang J, Jiang XB, Mou YG, Chen ZP.  Treatment of primary intracranial germ cell tumors: Single center experience with 42 clinically diagnosed cases. Oncotarget, 2016 Sep 13;7(37):60665-60675. doi: 10.18632/oncotarget.10218.
    45.Hua-Fu Zhao 1,3† , Jing Wang 1,2† , Hao-Ran Jiang 4 , Zhong-Ping Chen 2* and Shing-Shun Tony To. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition, Journal of Experimental & Clinical Cancer Research, (2016) 35:78
    46.Feng HB, Wang J, Jiang HR, Mei X, Zhao YY, Chen FR, Qu Y, Sai K, Guo CC, Yang QY, Zhang ZP, Chen ZP. β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1. STEM CELLS T RANSLATIONAL MEDICINE , 2017;6:830–839. Published Ahead of Print on October 7, 2016 as 10.5966/sctm.2016-0009.
    47.Zhang J, Zhang XH, Wang ZF, Li YP, Zhu ZQ, Sun JC, Chen ZH, Wu SY, Sai K, Wang J, Mou YG, Chen ZP. Transforaminal Resection of Cervical Dumbbell Schwannomas in Patients with Additional Tumors. World Neurosurg. World Neurosurg. 2017 Feb;98:768-773. Published online 2016 Nov 17. pii: S1878-8750(16)31185-8. doi: 10.1016/j.wneu.2016.11.037.
    48.Mei X, Chen YS, Chen FR, Xi SY, Chen ZP. Glioblastoma stem cell differentiation into endothelial cells evidenced through live cell imaging Running title: Live cell imaging of GSCs CD34 expression. Neuro Oncol. 2017 Mar 8. doi: 10.1093/neuonc/nox016. [Epub ahead of print]
    电影票房49.Ke C, Wang J, Xi S, Li KK, Luo J, Chen Z, Wang J, Chen ZP. An unusual combination of mirror-image dextrocardia with familial medulloblastoma : Is there a histogenetic relationship? World Neurosurg. 2017 Aug 24. pii: S1878-8750(17)31395-5. doi: 10.1016/j.wneu.2017.08.094. [Epub ahead of print]

    地址:廣州市東風東路651 號,郵編 510060
    電話、傳真:020-87343310
    E-Mail: chenzhp@sysucc.org.cn


    更新時間:2017年10月11日

訪客通道
員工通道
關注腫瘤醫院
留言建議 ×